Aventis Defense Against Sanofi Begins With Genasense; Ketek, Exubera Also Overlooked, Firm Says
This article was originally published in The Pink Sheet Daily
All three brands have blockbuster potential, Aventis says. The company predicts growth of 7%-8% in 2004 revenues, but says divestments of older brands may help enhance margins.
You may also be interested in...
The filing is the second of four supplements planned for the oncologic over the next year. A prostate cancer sNDA was submitted earlier in the year; filings for gastric cancer and head and neck cancer are expected.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.